Publication Information

{'id': 'https://openalex.org/W4220997777', 'doi': 'https://doi.org/10.1158/1538-7445.sabcs21-p1-18-35', 'title': 'Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level <i>FGFR1</i> amplification: Preliminary data from a phase 2 study', 'display_name': 'Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level <i>FGFR1</i> amplification: Preliminary data from a phase 2 study', 'publication_year': 2022, 'publication_date': '2022-02-15', 'ids': {'openalex': 'https://openalex.org/W4220997777', 'doi': 'https://doi.org/10.1158/1538-7445.sabcs21-p1-18-35'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.sabcs21-p1-18-35', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5009582590', 'display_name': 'Senthil Damodaran', 'orcid': 'https://orcid.org/0000-0002-2470-0891'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Senthil Damodaran', 'raw_affiliation_strings': ['MD Anderson Cancer Center, Houston, TX;'], 'affiliations': [{'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, TX;', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5061962242', 'display_name': 'Nisha Unni', 'orcid': 'https://orcid.org/0000-0003-1549-4720'}, 'institutions': [{'id': 'https://openalex.org/I867280407', 'display_name': 'The University of Texas Southwestern Medical Center', 'ror': 'https://ror.org/05byvp690', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I867280407']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Nisha Unni', 'raw_affiliation_strings': ['University of Texas Southwestern Medical Center, Dallas, TX;'], 'affiliations': [{'raw_affiliation_string': 'University of Texas Southwestern Medical Center, Dallas, TX;', 'institution_ids': ['https://openalex.org/I867280407']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5090729537', 'display_name': 'Karthik V. Giridhar', 'orcid': 'https://orcid.org/0000-0003-4640-9197'}, 'institutions': [{'id': 'https://openalex.org/I4210125099', 'display_name': 'Mayo Clinic in Arizona', 'ror': 'https://ror.org/03jp40720', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1330342723', 'https://openalex.org/I4210125099']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Karthik V. Giridhar', 'raw_affiliation_strings': ['Mayo Clinic, Rochester, MN;'], 'affiliations': [{'raw_affiliation_string': 'Mayo Clinic, Rochester, MN;', 'institution_ids': ['https://openalex.org/I4210125099']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5109178293', 'display_name': 'Brooke Daniel', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210135086', 'display_name': 'Tennessee Oncology', 'ror': 'https://ror.org/03754ky26', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210135086']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Brooke Daniel', 'raw_affiliation_strings': ['Tennessee Oncology, Chattanooga, TN;'], 'affiliations': [{'raw_affiliation_string': 'Tennessee Oncology, Chattanooga, TN;', 'institution_ids': ['https://openalex.org/I4210135086']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5026261167', 'display_name': 'Sacha J. Howell', 'orcid': 'https://orcid.org/0000-0001-8141-6515'}, 'institutions': [{'id': 'https://openalex.org/I4210133995', 'display_name': 'The Christie NHS Foundation Trust', 'ror': 'https://ror.org/03v9efr22', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210133995']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Sacha Howell', 'raw_affiliation_strings': ['The Christie NHS Foundation Trust, Manchester, United Kingdom'], 'affiliations': [{'raw_affiliation_string': 'The Christie NHS Foundation Trust, Manchester, United Kingdom', 'institution_ids': ['https://openalex.org/I4210133995']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5057379395', 'display_name': 'Luís Costa', 'orcid': 'https://orcid.org/0000-0002-4782-7318'}, 'institutions': [{'id': 'https://openalex.org/I4210114390', 'display_name': 'Centro Hospitalar Lisboa Norte', 'ror': 'https://ror.org/020sr6z07', 'country_code': 'PT', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210114390']}], 'countries': ['PT'], 'is_corresponding': False, 'raw_author_name': 'Luis Costa', 'raw_affiliation_strings': ['Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal'], 'affiliations': [{'raw_affiliation_string': 'Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal', 'institution_ids': ['https://openalex.org/I4210114390']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5024838193', 'display_name': 'Marta Ferreira', 'orcid': 'https://orcid.org/0000-0002-3680-8613'}, 'institutions': [{'id': 'https://openalex.org/I4210111164', 'display_name': 'IPO Porto', 'ror': 'https://ror.org/027ras364', 'country_code': 'PT', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210111164']}], 'countries': ['PT'], 'is_corresponding': False, 'raw_author_name': 'Marta Ferreira', 'raw_affiliation_strings': ['Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal'], 'affiliations': [{'raw_affiliation_string': 'Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal', 'institution_ids': ['https://openalex.org/I4210111164']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5029250198', 'display_name': 'Masashi Shimura', 'orcid': 'https://orcid.org/0000-0003-1233-4588'}, 'institutions': [{'id': 'https://openalex.org/I4210120269', 'display_name': 'Taiho Pharmaceutical (Japan)', 'ror': 'https://ror.org/02v50dx14', 'country_code': 'JP', 'type': 'company', 'lineage': ['https://openalex.org/I4210120269']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Masashi Shimura', 'raw_affiliation_strings': ['Taiho Pharmaceutical Co., Ltd., Tokyo, Japan'], 'affiliations': [{'raw_affiliation_string': 'Taiho Pharmaceutical Co., Ltd., Tokyo, Japan', 'institution_ids': ['https://openalex.org/I4210120269']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5058426048', 'display_name': 'Gareth Tomlinson', 'orcid': 'https://orcid.org/0009-0002-7731-8829'}, 'institutions': [], 'countries': ['CA'], 'is_corresponding': False, 'raw_author_name': 'Gareth Tomlinson', 'raw_affiliation_strings': ['Taiho Pharma Canada, Inc., Oakville, ON, Canada'], 'affiliations': [{'raw_affiliation_string': 'Taiho Pharma Canada, Inc., Oakville, ON, Canada', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5113839517', 'display_name': 'Maciej Gil', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210124059', 'display_name': 'Taiho Oncology (United States)', 'ror': 'https://ror.org/02z43nn16', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210124059']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Maciej Gil', 'raw_affiliation_strings': ['Taiho Oncology, Inc., Princeton, NJ;'], 'affiliations': [{'raw_affiliation_string': 'Taiho Oncology, Inc., Princeton, NJ;', 'institution_ids': ['https://openalex.org/I4210124059']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5060044961', 'display_name': 'Nicholas C. Turner', 'orcid': 'https://orcid.org/0000-0001-8937-0873'}, 'institutions': [{'id': 'https://openalex.org/I4210121186', 'display_name': 'Royal Marsden Hospital', 'ror': 'https://ror.org/034vb5t35', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1325846038', 'https://openalex.org/I4210121186']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Nicholas Turner', 'raw_affiliation_strings': ['Royal Marsden Hospital, London, United Kingdom'], 'affiliations': [{'raw_affiliation_string': 'Royal Marsden Hospital, London, United Kingdom', 'institution_ids': ['https://openalex.org/I4210121186']}]}], 'institution_assertions': [], 'countries_distinct_count': 5, 'institutions_distinct_count': 10, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.257, 'has_fulltext': False, 'cited_by_count': 2, 'citation_normalized_percentile': {'value': 0.573058, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 70, 'max': 76}, 'biblio': {'volume': '82', 'issue': '4_Supplement', 'first_page': 'P1', 'last_page': '35'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T12287', 'display_name': 'Fibroblast Growth Factor Research', 'score': 0.9972, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T12287', 'display_name': 'Fibroblast Growth Factor Research', 'score': 0.9972, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T11287', 'display_name': 'Cancer Genomics and Diagnostics', 'score': 0.9497, 'subfield': {'id': 'https://openalex.org/subfields/1306', 'display_name': 'Cancer Research'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T12829', 'display_name': 'Advanced Breast Cancer Therapies', 'score': 0.9421, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/fulvestrant', 'display_name': 'Fulvestrant', 'score': 0.8308579}, {'id': 'https://openalex.org/keywords/tolerability', 'display_name': 'Tolerability', 'score': 0.570376}, {'id': 'https://openalex.org/keywords/regimen', 'display_name': 'Regimen', 'score': 0.41542566}], 'concepts': [{'id': 'https://openalex.org/C2780482068', 'wikidata': 'https://www.wikidata.org/wiki/Q5508491', 'display_name': 'Fulvestrant', 'level': 5, 'score': 0.8308579}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.72412634}, {'id': 'https://openalex.org/C49418065', 'wikidata': 'https://www.wikidata.org/wiki/Q14914258', 'display_name': 'Fibroblast growth factor receptor 1', 'level': 4, 'score': 0.62433445}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5724912}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.57063794}, {'id': 'https://openalex.org/C2778375690', 'wikidata': 'https://www.wikidata.org/wiki/Q7814214', 'display_name': 'Tolerability', 'level': 3, 'score': 0.570376}, {'id': 'https://openalex.org/C2775930923', 'wikidata': 'https://www.wikidata.org/wiki/Q12859063', 'display_name': 'Metastatic breast cancer', 'level': 4, 'score': 0.52408093}, {'id': 'https://openalex.org/C72563966', 'wikidata': 'https://www.wikidata.org/wiki/Q1303415', 'display_name': 'Cohort', 'level': 2, 'score': 0.48763767}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.47016284}, {'id': 'https://openalex.org/C530470458', 'wikidata': 'https://www.wikidata.org/wiki/Q128581', 'display_name': 'Breast cancer', 'level': 3, 'score': 0.44211236}, {'id': 'https://openalex.org/C2781413609', 'wikidata': 'https://www.wikidata.org/wiki/Q7308373', 'display_name': 'Regimen', 'level': 2, 'score': 0.41542566}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.3290807}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.32285035}, {'id': 'https://openalex.org/C84606932', 'wikidata': 'https://www.wikidata.org/wiki/Q416496', 'display_name': 'Estrogen receptor', 'level': 4, 'score': 0.18360388}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.14123747}, {'id': 'https://openalex.org/C74373430', 'wikidata': 'https://www.wikidata.org/wiki/Q24727126', 'display_name': 'Fibroblast growth factor', 'level': 3, 'score': 0.10129589}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.sabcs21-p1-18-35', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.83, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4221067269', 'https://openalex.org/W3194613194', 'https://openalex.org/W3177199358', 'https://openalex.org/W3161515104', 'https://openalex.org/W3012234284', 'https://openalex.org/W2970181139', 'https://openalex.org/W2944020043', 'https://openalex.org/W2508852616', 'https://openalex.org/W2318928440', 'https://openalex.org/W2315340856'], 'abstract_inverted_index': {'Abstract': [0], 'Background:': [1], 'FGFR': [2, 47, 101], 'gene': [3], 'amplifications': [4, 15, 35], 'are': [5, 36], 'found': [6], 'in': [7, 17, 22, 44, 59, 75, 119, 125, 399, 404, 410, 422, 476, 507, 515, 523, 536, 542, 573, 577], '18%': [8], 'of': [9, 19, 144, 155, 167, 250, 256, 277, 321, 330, 339, 438, 452, 466, 495, 598], 'breast': [10, 581], 'cancers': [11], '(BCs),': [12], 'with': [13, 38, 121, 127, 160, 215, 290, 478, 491, 525, 575, 579], 'FGFR1': [14, 34, 62, 132, 168, 174, 296, 484, 586], 'occurring': [16], '≈10%': [18], 'cases,': [20], 'predominantly': [21], 'hormone': [23, 57], 'receptor-positive': [24], '(HR+),': [25], 'human': [26], 'epidermal': [27], 'growth': [28], 'factor': [29], 'receptor': [30], '2-negative': [31], '(HER2−)': [32], 'MBCs.': [33], 'associated': [37], 'resistance': [39, 55], 'to': [40, 53, 56, 112, 219, 396, 417, 471, 505], 'endocrine': [41], 'therapy,': [42], 'and': [43, 92, 188, 196, 206, 238, 248, 253, 307, 369, 384, 407, 436, 468, 474, 498], 'preclinical': [45, 73], 'experiments,': [46], 'pathway': [48], 'inhibition': [49], 'has': [50, 71], 'been': [51], 'shown': [52, 72], 'overcome': [54], 'therapy': [58], 'BC': [60, 76], 'harboring': [61, 79, 99, 129, 164, 294, 482, 584], 'amplifications.': [63, 81], 'Futibatinib,': [64], 'a': [65, 83, 149, 207, 216, 591], 'highly': [66], 'selective,': [67], 'irreversible': [68], 'FGFR1-4': [69], 'inhibitor,': [70], 'activity': [74, 91], 'xenograft': [77], 'models': [78], 'FGFR1/2': [80], 'In': [82, 391], 'phase': [84, 105, 592], '1': [85, 247, 252, 255, 411, 426], 'study,': [86], 'futibatinib': [87, 114, 232, 467, 521], 'showed': [88], 'promising': [89], 'clinical': [90], 'tolerability': [93], 'across': [94], 'tumor': [95], 'types,': [96], 'including': [97, 146], 'MBC,': [98], 'various': [100], 'aberrations.': [102], 'A': [103], 'multicohort': [104], '2': [106, 593], 'trial': [107], '(FOENIX-MBC2;': [108], 'NCT04024436)': [109], 'was': [110, 243, 273, 301, 323, 356, 431, 489], 'designed': [111], 'evaluate': [113], 'alone': [115], '(cohorts': [116], '1-3)': [117], 'or': [118, 131, 173, 269], 'combination': [120, 465, 501, 524, 574], 'fulvestrant': [122, 194, 240, 469, 526, 576], '(cohort': [123], '4)': [124], 'patients': [126, 159, 289, 309, 332, 343, 414, 424, 440, 477, 578], 'MBC': [128, 163, 293, 481], 'FGFR2': [130], 'amplifications,': [133], 'respectively.': [134], 'Here,': [135], 'we': [136], 'report': [137], 'preliminary': [138, 461], 'safety': [139, 150, 217, 462, 487], 'data': [140, 147, 278, 340, 434, 589], 'from': [141, 148, 590], 'cohort': [142, 283], '4': [143, 154, 213, 284, 400, 437], 'FOENIX-MBC2,': [145], 'lead-in.': [151], 'Methods:': [152], 'Cohort': [153, 212], 'FOENIX-MBC2': [156], 'enrolled': [157, 286, 432], 'adult': [158], 'HR+': [161, 291, 479], 'HER2−': [162, 292], 'high': [165], 'levels': [166], 'amplification': [169], '(FGFR1:CEN8': [170], 'ratio': [171], '≥5': [172], 'copy': [175], 'number': [176], '≥10': [177], 'signals': [178], 'per': [179], 'cell),': [180], 'Eastern': [181], 'Cooperative': [182], 'Oncology': [183], 'Group': [184], 'performance': [185], 'status': [186], '0-1,': [187], 'adequate': [189], 'organ': [190], 'function.': [191], 'Patients': [192, 229, 261], 'were': [193, 262, 334, 378, 389, 420, 441, 447, 513], 'naive': [195], 'had': [197, 285, 310], 'previously': [198], 'received': [199, 230, 311], '1-2': [200], 'endocrine-containing': [201], 'therapies,': [202], '≤1': [203], 'chemotherapy': [204], 'regimen,': [205], 'CDK4/6': [208], 'inhibitor': [209], '(if': [210], 'eligible).': [211], 'began': [214], 'lead-in': [218], 'assess': [220], 'dose-limiting': [221], 'toxicities': [222], '(DLTs)': [223], 'during': [224], 'the': [225, 453, 464, 492, 499, 519, 537, 599], 'first': [226], 'treatment': [227, 322, 336, 408, 427, 500], 'cycle.': [228, 260], 'oral': [231], '20': [233, 528], 'mg': [234, 242, 529], 'once': [235, 530], 'daily': [236], 'continuously,': [237], 'intramuscular': [239], '500': [241], 'administered': [244], 'on': [245, 459], 'days': [246], '15': [249], 'cycle': [251, 428], 'day': [254], 'every': [257], 'subsequent': [258], '28-day': [259], 'treated': [263], 'until': [264], 'disease': [265], 'progression,': [266], 'unacceptable': [267], 'toxicity,': [268], 'another': [270], 'discontinuation': [271, 409], 'criterion': [272], 'met.': [274], 'Results:': [275], 'As': [276, 510], 'cutoff': [279], '(March': [280], '31,': [281], '2021),': [282], '8': [287, 331], 'female': [288], 'high-level': [295, 483, 585], 'amplification.': [297, 485], 'The': [298, 318, 352, 486], 'median': [299, 319], 'age': [300], '55.5': [302], 'years': [303], '(range:': [304, 326], '31-62': [305], 'years),': [306], 'all': [308], '≥2': [312], 'prior': [313], 'therapies': [314], 'for': [315, 381, 444], 'advanced/metastatic': [316], 'BC.': [317], 'duration': [320], '8.0': [324], 'weeks': [325], '3.0-32.7': [327], 'weeks);': [328], '3': [329, 405], '(38%)': [333], 'continuing': [335], 'at': [337], 'time': [338], 'cutoff.': [341], 'All': [342], 'experienced': [344, 449], 'treatment-related': [345], 'adverse': [346, 387], 'events': [347, 377, 388], '(TRAEs;': [348], 'grade': [349, 375], '≥3:': [350], '25%).': [351], 'most': [353], 'common': [354], 'TRAE': [355], 'hyperphosphatemia': [357, 382], '(88%),': [358], 'followed': [359], 'by': [360, 450], 'constipation': [361], '(62%),': [362], 'transaminase': [363], 'elevation': [364], '(50%),': [365], 'dry': [366], 'mouth': [367], '(38%),': [368], 'alopecia': [370], '(38%).': [371], 'Among': [372], 'these': [373, 460], 'TRAEs,': [374], '≥3': [376], 'only': [379], 'reported': [380], '(12%),': [383], 'no': [385, 413, 511], 'serious': [386], 'reported.': [390], 'this': [392], 'cohort,': [393, 541], 'TRAEs': [394], 'led': [395], 'dose': [397, 522], 'reductions': [398], 'patients,': [401, 406, 518], 'dosing': [402], 'interruptions': [403], 'patient;': [412], 'died': [415], 'due': [416], 'TRAEs.': [418], 'DLTs': [419, 446, 512], 'evaluated': [421, 535], '5': [423, 454, 516], 'following': [425], '(1': [429], 'patient': [430], 'after': [433], 'cutoff,': [435], '9': [439], 'not': [442, 448, 503], 'evaluable': [443, 455, 517], 'DLTs);': [445], 'any': [451], 'patients.': [456], 'Conclusions:': [457], 'Based': [458], 'results,': [463], 'appears': [470], 'be': [472, 534], 'safe': [473], 'tolerable': [475], 'HER−': [480], 'profile': [488], 'consistent': [490], 'individual': [493], 'profiles': [494], 'both': [496], 'drugs,': [497], 'did': [502], 'appear': [504], 'result': [506], 'synergistic': [508], 'toxicity.': [509], 'observed': [514], 'recommended': [520], 'is': [527, 545], 'daily.': [531], 'Efficacy': [532], 'will': [533], 'complete': [538], '28-patient': [539], 'post-lead-in': [540], 'which': [543], 'enrollment': [544], 'ongoing.': [546], 'Citation': [547], 'Format:': [548], 'Senthil': [549], 'Damodaran,': [550], 'Nisha': [551], 'Unni,': [552], 'Karthik': [553], 'V.': [554], 'Giridhar,': [555], 'Brooke': [556], 'Daniel,': [557], 'Sacha': [558], 'Howell,': [559], 'Luis': [560], 'Costa,': [561], 'Marta': [562], 'Ferreira,': [563], 'Masashi': [564], 'Shimura,': [565], 'Gareth': [566], 'Tomlinson,': [567], 'Maciej': [568], 'Gil,': [569], 'Nicholas': [570], 'Turner.': [571], 'Futibatinib': [572], 'metastatic': [580], 'cancer': [582], '(MBC)': [583], 'amplification:': [587], 'Preliminary': [588], 'study': [594], '[abstract].': [595], 'In:': [596], 'Proceedings': [597], '2021': [600, 606], 'San': [601, 609], 'Antonio': [602], 'Breast': [603], 'Cancer': [604, 615], 'Symposium;': [605], 'Dec': [607], '7-10;': [608], 'Antonio,': [610], 'TX.': [611], 'Philadelphia': [612], '(PA):': [613], 'AACR;': [614], 'Res': [616], '2022;82(4': [617], 'Suppl):Abstract': [618], 'nr': [619], 'P1-18-35.': [620]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4220997777', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2022, 'cited_by_count': 1}], 'updated_date': '2024-12-16T05:51:37.517251', 'created_date': '2022-04-03'}